更新于：2024-11-01

Libido disorder NOS

性欲障碍 NOS

更新于：2024-11-01

基本信息

别名

Libido disorder、Libido disorder NOS、リビドー障害

+ [3]

简介-

关联

项与性欲障碍 NOS 相关的药物

Bremelanotide Acetate

布美诺肽

靶点

MC4R

作用机制

MC4R激动剂

在研机构

Palatin Technologies, Inc. [+1]

原研机构

AMAG Pharmaceuticals, Inc.

在研适应症

心理性性功能障碍 [+2]

非在研适应症

勃起功能障碍 [+4]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2019-06-21

项与性欲障碍 NOS 相关的临床试验

CTR20201537 / Completed临床1期

评估Bremelanotide（BMT）在中国健康女性受试者中的药代动力学、安全性和耐受性的单中心、开放性临床研究

（1）评估在中国健康女性受试者中单次腹部皮下注射1.75 mg BMT的药代动力学特征。（2）评估在中国健康女性受试者中单次腹部皮下注射1.75 mg BMT的安全性和耐受性。

开始日期2020-10-16

申办/合作机构

Catalent Belgium SA

[+2]

EUCTR2009-010549-30-IT / Not yet recruitingN/AIIT

PRAMIPEXOLE IN THE MALE LIBIDO FAILURE : A PHASE II, off-label, pilot study - ND

开始日期2009-12-16

申办/合作机构-

NCT00289926 / Completed临床3期IIT

A Randomised, Double-blind, Placebo-controlled, Parallel-group, 52-week Study to Evaluate the Efficacy and Safety of Oral DHEA Therapy for Postmenopausal Women on Sexual Function, Wellbeing and Vasomotor Symptoms

This study is designed to evaluate the efficacy and safety of oral Dehydroepiandrosterone (DHEA) 50mg daily, for 12 months in naturally menopausal women with low libido who are not receiving systemic oestrogen or oestrogen- progestin therapy.
Efficacy measures for the present study are effects on sexual function, wellbeing and menopausal symptoms. Safety measures will include endometrial assessment by transvaginal ultrasound (TVU), vital signs, lipid profiles, general electrolytes, effects on glucose metabolism and reports of adverse events.

开始日期2006-02-01

申办/合作机构

Monash University

100 项与性欲障碍 NOS 相关的临床结果

登录后查看更多信息

100 项与性欲障碍 NOS 相关的转化医学

登录后查看更多信息

0 项与性欲障碍 NOS 相关的专利（医药）

登录后查看更多信息

项与性欲障碍 NOS 相关的文献（医药）

2023-12-01·PEC Innovation

Knowledge of type 2 diabetic patients followed for less than 5 years in primary care in the western region of Reunion Island: a cross-sectional pilot study

Article

作者: Gatina, Jean-Hugues ; Chane-Po, David ; Legrand, Florian ; Leruste, Sébastien

BackgroundThe learning needs of newly diagnosed diabetic patients followed up in medical offices in Reunion Island are unknown, although necessary for the improvement of education programmes and disease control.AimTo assess the knowledge of type 2 diabetic patients in primary care followed for less than 5 years.MethodA cross-sectional study was carried out, using a self-questionnaire to assess patients' knowledge of diabetes, complications, follow-up, diet and physical activity. Patients were recruited from medical offices in the western region of Reunion Island.ResultsFrom 23^rd April to 31^st July 2021, 89 patients were included. The knowledge level of the total sample was moderate (mean correct answers 65 % ± 17). The best knowledge levels were in the areas "generalities on diabetes" and "complications", while the lowest levels were in the categories "follow-up" and "diet and physical activity". Glycated haemoglobin, libido disorders, frequency of urinalysis and dental consultation, and the recommended diet for patients with diabetes which is the same as for the general population, were the least known concepts.ConclusionThis study revealed gaps in patients' knowledge that could be used to improve education programmes which in turn could reduce or prevent diabetes complications.

2022-06-01·Drug Safety2区 · 医学

Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database

2区 · 医学

Article

作者: Matos, Cristiano ; van Hunsel, Florence ; Valeiro, Carolina ; Scholl, Joep

INTRODUCTIONSexual dysfunction (SD) is a problem that can affect any phase of the sexual response cycle (such as sexual desire, arousal and orgasm) and individuals of any age. SD can be caused by physical reasons, such as medical conditions, alcoholism or drug abuse; psychological factors, such as stress and anxiety; and different medicines, such as selective serotonin reuptake inhibitors (SSRIs), and their associated adverse effects.AIMThe aim of this study was to characterise drugs suspected to have caused SD adverse drug reactions (ADRs) in patients, by conducting a descriptive study based on pharmacovigilance reports.METHODSReports submitted to the Netherlands Pharmacovigilance Centre Lareb from January 2003 to December 2019 were used to investigate drug-induced sexual disorders. Selected reports had at least one ADR reported in the Medical Dictionary for Regulatory Activities (MedDRA^®) System Organ Class (SOC) 'Reproductive system and breast disorders' and the SOC 'Psychiatric disorders' relating to sexual disorders and corrected for drug utilisation (expenditure) for the Dutch population.RESULTSA total of 2815 SD ADRs were reported in the observed period. Data were divided according to three variables: pharmacotherapeutic group, the drug itself, and sex. A total of 722 different SD/pharmacotherapeutic group pairs were observed. The pharmacotherapeutic groups with the highest frequency of SD reports were SSRIs (n = 488, 17.58%), other antidepressants (n = 172, 6.20%) and HMG-CoA reductase inhibitors (n = 149, 5.37%). Distinguishing ADRs by sex, men suffered more from erectile dysfunction, decreased libido and ejaculation disorders, while among women, libido disorders, dyspareunia and SD were the most common ADRs.CONCLUSIONDifferent reactions and disproportionality of reactions were detected between the sexes. Antidepressants, antihypertensives, oral contraceptives, α-blockers, and anti-androgens were the pharmacotherapeutic groups with the highest number of SD reports and corresponding high odds ratios.

2021-01-01·The World Journal of Men's Health2区 · 医学

Oral Testofen, L-Citrulline, Resveratrol, and Caffeine Supplement Drink Improves Sexual Function in Men with Phosphodiesterase 5 Inhibitors: Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study

2区 · 医学

ArticleOA

作者: Koyama, Taro ; Nozaki, Taiji ; Tsujimura, Akira ; Hiramatsu, Ippei ; Miyoshi, Yuto ; Ogasa, Taiki ; Uesaka, Yuka ; Miyoshi, Miho ; Ishikawa, Keisuke ; Shirai, Masato

PURPOSESexuality is very important for men's health. Currently, phosphodiesterase type 5 inhibitors (PDE5i) remain the first-line therapy for erectile dysfunction, and no other oral drugs or drinks are approved and used clinically to treat male libido or orgasm dysfunction. In reference to a pharmaceutical dosage document, growing health consciousness is said to have boosted yearly sales of supplement drinks to more than 170 billion yen (1.58 billion US dollars) in Japan. We have created a supplement drink comprised of testofen, L-citrulline, resveratrol, and caffeine. We hypothesized that our supplement drink would be effective for men with sexual dysfunction, and especially libido dysfunction.MATERIALS AND METHODSIn this study, men with sexual dysfunction received a placebo drink for 14 days or our supplement drink (testofen, 600 mg/d; L-citrulline, 800 mg/d; resveratrol, 300 mg/d; and caffeine, 40 mg/d) for another 14 days separated by a 7-day washout period. Patients continued on-demand use of PDE5i. The International Index of Erectile Function (IIEF) score and adverse events were assessed.RESULTSTwenty patients aged 30-7 years old were enrolled in and concluded the study with no adverse events experienced. The IIEF domains of desire frequency, erection frequency, erection firmness, erection confidence, intercourse satisfaction, ejaculation frequency, orgasm frequency, and overall satisfaction were significantly improved with our supplement drink.CONCLUSIONSThis is the first study to show that our supplement drink may not only be effective for erection but also for libido, orgasm, and ejaculation.